Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31243103 | 0.77 | ALDH1A1 (0.44) | KEAP1PTPRCADORA2A | |
| SCHEMBL5841832 | 0.77 | ALDH1A1 (0.44) | KEAP1PTPRCADORA2A | |
| SCHEMBL5089542 | 0.75 | EGLN2 (0.33) | EGLN2CA12CA1CA2CA4 | |
| SCHEMBL29429038 | 0.69 | ALDH1A1 (0.58) | EGLN2CA12CA1CA2CA4 | |
| SCHEMBL4630043 | 0.69 | ALDH1A1 (0.58) | EGLN2CA12CA1CA2CA4 | |
| SCHEMBL6347456 | 0.69 | EGLN2 (0.44) | EGLN2CA12CA1CA2CA4 | |
| SCHEMBL18762688 | 0.69 | EGLN2 (0.39) | EGLN2CA12CA1CA2CA4 | |
| SCHEMBL28641386 | 0.69 | CYP3A4 (0.35) | KEAP1 | |
| SCHEMBL24254918 | 0.68 | CYP3A4 (0.47) | KEAP1PTPRCADORA2A | |
| SCHEMBL11309110 | 0.67 | TTR (0.47) | EGLN2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410868-B2 | Method for fabricating a nonvolatile memory element and a nonvolatile memory element | INFINEON TECHNOLOGIES AG (DE) | 2008-08-12 | — | — | US | disclosed |
| US-20060234418-A1 | Method for fabricating a nonvolatile memory element and a nonvolatile memory element | POLARIS INNOVATIONS LIMITED (IE) | 2006-10-19 | — | — | US | disclosed |
| US-20060175604-A1 | Novel type of attachment of organic molecules to a silicon surface for producing memory elements having organic constituents | INFINEON TECHNOLOGIES AG (DE) | 2006-08-10 | — | — | US | disclosed |
| EP-1684304-A2 | Binding of organic molecules to a silicon surface for fabrication of storage elements with organic compounds | Infineon Technologies AG (DE) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060175604-A1 | Novel type of attachment of organic molecules to a silicon surface for producing memory elements having organic constituents | L1CAM, KCNN2, KCNN1 | EGLN2 1908/4885CA12 438/4885CA1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.